RecruitingPhase 2NCT06565273

Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
Principal Investigator
José Costa, MD
Unidade Local de Saúde do Alto Minho, EPE
Intervention
FBL-MTX(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06565273 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials